Hypoxia-Inducible Factor 1 and Preeclampsia: A New Perspective

Albogami, Sarah; Al-Kuraishy, Hayder M; Al-Maiahy, Thabat J; Al-Buhadily, Ali K; Al-Gareeb, Ali I; Alorabi, Mohammed; Alotaibi, Saqer S.; Waard, Michel De; Sabatier, Jean‐Marc; Saad, Hebatallah M.; Batiha, Gaber El‐Saber

doi:10.1007/s11906-022-01225-1

Cited by 19 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In keeping with its essential physiological role, HIF-1 has been demonstrated to contribute in a widest spectrum of human pathologies, from oncological to neurodegenerative and infectious [ 15 ]. Not surprisingly, HIF-1 is also strongly involved in various gynecological diseases—preeclampsia [ 27 ], polycystic ovary syndrome [ 28 ], cancer [ 29 ], endometriosis [ 30 ] and others [ 31 , 32 ].…”

Section: The Role Of Hypoxia-inducible Factor In Uterine Fibroidsmentioning

confidence: 99%

Pathways of Hypoxia-Inducible Factor (HIF) in the Orchestration of Uterine Fibroids Development

Fedotova

Барышева

Бушуева

2023

Life

View full text Add to dashboard Cite

Uterine fibroids (UF) are common benign tumors in women. The course of UF is associated with troubling symptoms and the development of infertility and pregnancy pathology. Surgical treatment even implies hysterectomy, while pharmacological interventions are modestly effective. Classically, hypoxic metabolism is considered a hallmark of malignant tumor. However, the role of hypoxia-induced factor (HIF) is significant in benign tumors as well. Herein, we briefly review the basic biology of HIF-family proteins, outlining their possible roles in UF. Apart from theoretical justifications, we summarized 15 studies reporting increased expression of HIFs and downstream factors in UF samples. Altogether, data suggest that increased expression of the HIF-protein and altered expression of its dependent genes are presumed to be the factors leading to UF development. Thus, even without being a malignant tumor, UF is characterized by the strong involvement of HIF. This novel insight may give rise to further research in the direction of finding new prognostic markers and effective medicines against UF.

show abstract

Section: The Role Of Hypoxia-inducible Factor In Uterine Fibroidsmentioning

confidence: 99%

Pathways of Hypoxia-Inducible Factor (HIF) in the Orchestration of Uterine Fibroids Development

Fedotova

Барышева

Бушуева

2023

Life

View full text Add to dashboard Cite

show abstract

“…As a component of HIF-1, HIF-1α regulates multiple pathways mediating abnormal PE placental vascular remodeling [44,45] . Primarily, HIF-1α can activate anti-angiogenic and inhibit pro-angiogenic factors, such as soluble FMS-Like Tyrosine kinase-1 (FLT1), VEGFA, Notch homolog 1 [46] . HIF-1α also enhances placental inflammation and dysfunction by increasing the production of p38MAPK and NLRP3 inflammatory vesicles [46] .…”

Section: Resultsmentioning

confidence: 99%

Aspirin in Invasive Function of Hypoxic HTR-8/SVneo by Modulating the Urothelial Carcinoma-Associated 1/ microRNA-18a/HIF-1α Pathway

Song,

Zhao,

Chen

et al. 2024

IJPS

View full text Add to dashboard Cite

Song et al.: Mechanism and Potential of Noncoding Ribonucleic Acid in PreeclampsiaPreeclampsia is a disease associated with developmental defects in the placenta. However, the pathogenesis of preeclampsia has not been precisely elucidated. Extensive studies have found that noncoding ribonucleic acid is involved in transcription and post-transcriptional translation. In the present study, we expounded on the pathogenic mechanism and diagnostic potential of noncoding ribonucleic acid in preeclampsia. We obtained the differentially expressed long noncoding ribonucleic acid urothelial carcinoma-associated 1 from the gene expression omnibus dataset. Urothelial carcinoma-associated 1 participated as a core gene in the construction of the competing endogenous ribonucleic acid network. The receiver operating characteristic curves were used to construct a diagnostic model for preeclampsia. Besides, the biological processes that urothelial carcinoma-associated 1 may influence in preeclampsia development were explored. Then, we detected urothelial carcinoma-associated 1, microRNA-18a, and hypoxia-inducible factor-1 alpha expressions by real-time quantitative polymer chain reaction and Western blotting. Based on the HTR-8/SVneo cell hypoxia model, we altered the expression of urothelial carcinoma-associated 1 or microRNA-18a by transfection. Cell counting kit-8, transwell, and wound healing assay were applied to treated cells to detect changes in their biological behaviors. Clinical samples confirmed that urothelial carcinoma-associated 1 and hypoxia-inducible factor-1 alpha messenger ribonucleic acid were more abundant in the placenta of patients with preeclampsia, while microRNA-18a was deficient. Urothelial carcinoma-associated 1 regulated the expression of hypoxia-inducible factor-1 alpha via microRNA-18a, promoting trophoblastic cell migration, invasion, and proliferation. Aspirin treatment significantly repaired the invasive function of drug-induced hypoxic trophoblasts, and the expression levels of these three genes were altered. Thus, we concluded that urothelial carcinoma-associated 1/microRNA-18a/hypoxia-inducible factor-1 alpha forms a molecular pathway that affects the biological behaviors of trophoblast cells and participates in the pathogenesis of preeclampsia.

show abstract

“…HIF-1α can induce the expression of anti-angiogenic factors and inhibits the expression of pro-angiogenic factors. In addition, HIF-1α induces renin angiotensin system (RAS) expression by increasing circulating angiotensin II (AngII), leading to endothelial dysfunction and peripheral vasoconstriction, which in turn triggers PE [ 104 ]. piR-823 regulates the glucose-6-phosphate dehydrogenase (G6PD)/HIF-1α pathway by enhancing the expression of the key downstream signaling molecule G6PD, thereby inhibiting the ubiquitination of HIF-α and up-regulating the expression of HIF-α, prolonging its half-life, and reducing the intracellular ROS content to regulate the hypoxic environment [ 105 ].…”

Section: Pirnas: Potential Epigenetic Regulators Of Pe Pathogenesismentioning

confidence: 99%

Potential molecular mechanisms and clinical implications of piRNAs in preeclampsia: a review

Ma,

Hou,

Zong

et al. 2024

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Preeclampsia is a multisystem progressive condition and is one of the most serious complications of pregnancy. Owing to its unclear pathogenesis, there are no precise and effective therapeutic targets for preeclampsia, and the only available treatment strategy is to terminate the pregnancy and eliminate the clinical symptoms. In recent years, non-coding RNAs have become a hotspot in preeclampsia research and have shown promise as effective biomarkers for the early diagnosis of preeclampsia over conventional biochemical markers. PIWI-interacting RNAs, novel small non-coding RNA that interact with PIWI proteins, are involved in the pathogenesis of various diseases at the transcriptional or post-transcriptional level. However, the mechanisms underlying the role of PIWI-interacting RNAs in the pathogenesis of preeclampsia remain unclear. In this review, we discuss the findings of existing studies on PIWI-interacting RNA biogenesis, functions, and their possible roles in preeclampsia, providing novel insights into the potential application of PIWI-interacting RNAs in the early diagnosis and clinical treatment of preeclampsia.

show abstract

Hypoxia-Inducible Factor 1 and Preeclampsia: A New Perspective

Cited by 19 publications

References 40 publications

Pathways of Hypoxia-Inducible Factor (HIF) in the Orchestration of Uterine Fibroids Development

Pathways of Hypoxia-Inducible Factor (HIF) in the Orchestration of Uterine Fibroids Development

Aspirin in Invasive Function of Hypoxic HTR-8/SVneo by Modulating the Urothelial Carcinoma-Associated 1/ microRNA-18a/HIF-1α Pathway

Potential molecular mechanisms and clinical implications of piRNAs in preeclampsia: a review

Contact Info

Product

Resources

About